Roche cuts Genentech bid to $42 billion

ZURICH (Reuters) – Swiss drugmaker Roche Holding AG cut the price of its bid for outstanding shares in Genentech on Friday, confounding investor hopes of a sweetened offer for the 44 percent of the U.S. biotech company Roche does not already own.

Leave a Reply